Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1974 Jun;27(6):457–462. doi: 10.1136/jcp.27.6.457

Assay of rifampicin in serum

Jean M Dickinson 1, V R Aber 1, B W Allen 1, G A Ellard 1, D A Mitchison 1
PMCID: PMC478155  PMID: 4212955

Abstract

Two methods for the assay of rifampicin in serum are described. The first is a conventional plate diffusion method, measuring concentrations down to 0·02 μg/ml, and the second a chemical extraction followed by measurement of the inhibition of uptake of 14C-uridine by Staphylococcus aureus, which estimates in the range of 0·02 to 0·001 μg/ml. The methods were used to measure serum concentrations in man following doses of about 1050 mg and 75 mg rifampicin.

Full text

PDF
457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aquinas M., Allan W. G., Horsfall P. A., Jenkins P. K., Hung-Yan W., Girling D., Tall R., Fox W. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972 Mar 25;1(5803):765–771. doi: 10.1136/bmj.1.5803.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Canetti G., Djurovic V., Le Lirzin M., Thibier R., Lepeuple A. Etude comparative de l'évolution des taux sanguins de rifampicine chez l'homme par deux méthodes microbiologiques différentes. Rev Tuberc Pneumol (Paris) 1970;34(1):93–106. [PubMed] [Google Scholar]
  3. Dickinson J. M., Mitchison D. A. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle. 1970 Mar;51(1):82–94. doi: 10.1016/0041-3879(70)90131-5. [DOI] [PubMed] [Google Scholar]
  4. Furesz S., Scotti R., Pallanza R., Mapelli E. Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man. Arzneimittelforschung. 1967 May;17(5):534–537. [PubMed] [Google Scholar]
  5. Hartmann G., Honikel K. O., Knüsel F., Nüesch J. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta. 1967;145(3):843–844. doi: 10.1016/0005-2787(67)90147-5. [DOI] [PubMed] [Google Scholar]
  6. LLOYD J., MITCHISON D. A. A VERTICAL DIFFUSION METHOD FOR THE MICROBIOLOGICAL ASSAY OF ISONIAZID. J Clin Pathol. 1964 Nov;17:622–626. doi: 10.1136/jcp.17.6.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Maggi N., Vigevani A., Pallanza R. Desacetyl-rifamycins: preparation and antibacterial properties. Experientia. 1968 Mar 15;24(3):209–211. doi: 10.1007/BF02152772. [DOI] [PubMed] [Google Scholar]
  8. Mitchison D. A., Allen B. W., Miller A. B. Detection of rifampicin in urine by a simple microbiological assay. Tubercle. 1970 Sep;51(3):300–304. doi: 10.1016/0041-3879(70)90023-1. [DOI] [PubMed] [Google Scholar]
  9. Poole G., Stradling P., Worlledge S. Potentially serious side effects of high-dose twice-weekly rifampicin. Br Med J. 1971 Aug 7;3(5770):343–347. doi: 10.1136/bmj.3.5770.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sippel A., Hartmann G. Mode of action of rafamycin on the RNA polymerase reaction. Biochim Biophys Acta. 1968 Mar 18;157(1):218–219. doi: 10.1016/0005-2787(68)90286-4. [DOI] [PubMed] [Google Scholar]
  11. Umezawa H., Mizuno S., Yamazaki H., Nitta K. Inhibition of DNA-dependent RNA synthesis by rifamycins. J Antibiot (Tokyo) 1968 Mar;21(3):234–236. doi: 10.7164/antibiotics.21.234. [DOI] [PubMed] [Google Scholar]
  12. Wehrli W., Knüsel F., Schmid K., Staehelin M. Interaction of rifamycin with bacterial RNA polymerase. Proc Natl Acad Sci U S A. 1968 Oct;61(2):667–673. doi: 10.1073/pnas.61.2.667. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES